Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Sizheng Steven, Harrison, Stephanie R, Chan, Antoni, Clarke, Nick, Davis, Charlotte, Eddison, Joe, Gregory, William J, Jones, Gareth T, Marzo-Ortega, Helena, Murphy, Daniel J, Sandhu, Virinderjit, Sengupta, Raj, Siebert, Stefan, Thompson, Ben, Webb, Dale, Yates, Max, Gaffney, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183299/
https://www.ncbi.nlm.nih.gov/pubmed/37197377
http://dx.doi.org/10.1093/rap/rkad039
Descripción
Sumario:Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

Ejemplares similares